Table 2.
Main findings from other first-generation tau PET studies.
| Paper | Tracer | Clinical population | Findings |
|---|---|---|---|
| Schröter (2020) | [11C]PBB3 | 2 CBS, 7 PSP, 2 AD | Binding consistent with tau pathology in CBS, PSP, and AD |
| Ono (2017) | [11C]PBB3 | In vitro | Increased tracer binding to PSP tau sites |
| Chiotis (2018) | [18F]THK-5317 | 16 AD, 2 CBS | Tracer retention increased in CBS patients with disease progression, especially in basal ganglia and frontotemporal areas |
| Chiotis (2016) | [18F]THK-5317 | 1 CBD, 1 PSP, 9 AD, 13 MCI, 5 young HC, 4 old HC | Tracer binding consistent with CBD and PSP pathology; different distribution from AD patients |
| Ng (2017) | [18F]THK-5351 | 5 MCI, 2 AD, 1 PSP | Tracer uptake is reduced by MAO-B inhibitor, especially in the basal ganglia and thalamus |
| Kepe (2013) | [18F]FDDNP | 15 PSP, 9 PD, 5 HC | Binding consistent with PSP pathology; increased subcortical and cortical involvement with disease progression |